SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-062739
Filing Date
2018-10-18
Accepted
2018-10-18 16:01:42
Documents
9
Period of Report
2018-10-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-36860_48k.htm 8-K 38304
2 EX-1.1 a18-36860_4ex1d1.htm EX-1.1 327804
3 EX-5.1 a18-36860_4ex5d1.htm EX-5.1 10850
4 EX-99.1 a18-36860_4ex99d1.htm EX-99.1 10870
5 EX-99.2 a18-36860_4ex99d2.htm EX-99.2 11087
6 EX-99.3 a18-36860_4ex99d3.htm EX-99.3 107409
7 GRAPHIC g368604kii001.jpg GRAPHIC 2461
8 GRAPHIC g368604moi001.jpg GRAPHIC 6125
9 GRAPHIC g368604mmi001.jpg GRAPHIC 6125
  Complete submission text file 0001104659-18-062739.txt   528168
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 181128389
SIC: 2834 Pharmaceutical Preparations